KR20150129873A - Nanoparticles for genes drug delivery and method for preparing the same - Google Patents
Nanoparticles for genes drug delivery and method for preparing the same Download PDFInfo
- Publication number
- KR20150129873A KR20150129873A KR1020140056221A KR20140056221A KR20150129873A KR 20150129873 A KR20150129873 A KR 20150129873A KR 1020140056221 A KR1020140056221 A KR 1020140056221A KR 20140056221 A KR20140056221 A KR 20140056221A KR 20150129873 A KR20150129873 A KR 20150129873A
- Authority
- KR
- South Korea
- Prior art keywords
- sirna
- nanoparticles
- nanoparticle
- nucleic acid
- dielectric
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
The present invention relates to a nanoparticle for dielectric drug delivery and a method for producing the nanoparticle, and more particularly, to a nanoparticle for condensing and granulating a dielectric drug and coating the outer surface with hyaluronic acid to efficiently deliver the dielectric drug to the retina, ≪ / RTI >
Choroidal neovascularization (CNV) is a major cause of age-related macular degeneration (AMD), a disease that causes blindness. Although the number of patients with AMD is increasing as an aging society, complete therapies have yet to be developed. At present, photodynamic therapy and anti-VEGF (vascular endothelial growth factor) therapy are being used. Photodynamic therapy is a technique of injecting a light-sensitive photoreceptor (skin photosensitizer) , Light is selectively accumulated only in diseased cells and has a therapeutic effect. To treat CNV, the drug is injected intravenously and is activated in the eye by a laser to prevent the formation of new blood vessels. Anti-VEGF, Avastin and Lucentis are commonly used to treat CNV.
Recently, gene therapy for CNV treatment has been newly studied. Because mRNA and DNA can be transcribed into several proteins, gene therapy using RNA and DNA can be an effective treatment method.
Small interfering RNA (siRNA) is a short RNA of double helix structure composed of 19-22 nucleic acids. When it binds to the same messenger RNA (messenger RNA, mRNA) with its sense strand, (Elbashir, SM et al., 2001, Nature 411, 494-8) by degrading the mRNA associated with the RNA induced silencing complex (RISC). Various possibilities have been studied for the treatment of gene related diseases by utilizing the property of such siRNA which suppresses effective and precise expression of the same mRNA with a small amount, and the market for the therapeutic drug development using siRNA has been remarkably increased year by year .
However, enzyme instability and poor cell permeability of siRNA have been a major obstacle to practical clinical treatment. To solve this problem, various carriers have been developed and various molecules are bonded to siRNA itself. In order to prevent direct exposure to the enzyme and increase cell permeability, a cationic polymer or a lipid molecule and a peptide are electrostatically bound to an anionic siRNA to form a nano-sized complex having a cationic property as a whole, And at the same time, the interaction with the anion-like cell membrane is improved to increase the intracellular delivery efficiency. More specifically, 2-dioeloyl-3-trimethylammonium (DOTAP), polyethylenimine (PEI), chitosan groups, and poly L-lysine (PLL) have positive charge characteristics and high RNA solubility and cell penetration efficiency. However, they also exhibit strong positive charge transfer characteristics to target healthy liver or spleen cells or cytotoxicity.
Recently, modified cationic polymers such as glycol chitosan and branched PEI have been used to solve the cytotoxicity problem by lowering the positive charge intensity. However, decreasing the positive charge intensity has reduced the binding force between RNA and carrier, Lt; RTI ID = 0.0 > enzymes. ≪ / RTI >
[Reference patents]
Korean Patent Publication No. 10-2011-83919
Korean Patent No. 10-806088
The present invention provides a drug delivery system having high cytotoxicity and high gene transfer efficiency into the retina.
The present invention provides a genetic material delivery nanoparticle capable of reaching retinal nerve cells without degrading the genetic material by an enzyme.
One aspect of the present invention is a nucleic acid amplification method comprising: a core portion in which a nucleic acid targeting a gene and a cationic polymer are condensed by ionic interaction; And a hyaluronic acid outer layer coated on the outer surface of the core portion.
In another aspect, the present invention provides a method for producing a nucleic acid comprising the steps of: mixing a nucleic acid that targets a gene and a cationic polymer; And coating a hyaluronic acid outer layer with an electrostatic attraction on the outer surface of the condensed core portion.
The present invention relates to a nanoparticle for transferring a dielectric substance having a core and an outer shell structure surrounding the same, wherein the nucleic acid such as siRNA is condensed with a non-toxic cationic polymer in the form of a polymer, And the outer shell is coated with (-) charged hyaluronic acid to prevent aggregation with the vitreous meshwork structural materials that are charged (-) and the inner limiting of the retina The membrane can be reached. In addition, hyaluronic acid binds to CD44 of Mueller cells, allowing the structure of the retina to pass through the sub-retinal space through the transcytosis mechanism.
FIG. 1 is a conceptual diagram of a nano location for dielectric transfer according to an embodiment of the present invention.
FIG. 2 illustrates a method of preparing nanoparticles for dielectric transmission according to an embodiment of the present invention. Referring to FIG.
Fig. 3 shows the size distribution of nanoparticles and cores prepared in Example 1. Fig.
4 is a TEM image of nanoparticles prepared in Example 1. FIG.
FIG. 5 shows the results of a test in which the produced nanoparticles are transferred into retinal cells and a PCR in which anti-VEGF-A siRNA delivered by nanoparticles selectively inhibits VEGF-A expression.
FIG. 6 shows a result of observing the eye through a confocal microscope showing that the produced nanoparticles reach the
FIG. 7 shows the result of CNV inhibition experiment in mouse eyes using the prepared nanoparticles.
FIG. 8 shows the result of toxicity test using the prepared nanoparticles.
The present invention can be all accomplished by the following description. The following description should be understood to describe preferred embodiments of the present invention, but the present invention is not necessarily limited thereto.
FIG. 1 is a conceptual diagram of a nano location for dielectric transfer according to an embodiment of the present invention.
Referring to FIG. 1, the dielectric nanoparticles of the present invention include a
The
The
SiRNAs usable in the present invention are not particularly limited as long as they are used for therapeutic or research purposes and include siRNAs such as c-myc, c-myb, c-fos, c-jun, survivin, bcl- Or any siRNA that may be used or used for gene therapy or research such as VEGF, VEGF-B, VEGF-C, VEGF-D and PIGF. It is preferable that the siRNA can target vascular endothelial growth factor (VEGF) of the retina and inhibit its expression.
The cationic polymer may be at least one selected from the group consisting of polyethyleneimine, polyamine and polyvinylamine, and preferably branched PEI having relatively low toxicity may be used.
The core part may be formed by mixing the
The weight ratio of the nucleic acid and the cationic polymer may be 1: 0.1 to 3, preferably 1: 0.1 to 2, more preferably 1: 1.
The nucleic acid may have a weight average molecular weight of 3K to 30K, and the cationic polymer may have a weight average molecular weight of 10K.
The
The hyaluronic acid
The hyaluronic acid outer layer surrounding the core portion represents a negative charge, and thus the nanoparticles also exhibit a negative charge.
Various types of HA are suitable for the purposes of the present invention. Particularly, a HA having a large molecular weight and a small HA can be used, preferably 5 to 10 K, more preferably 5 K HA.
Hyaluronic acid (HA) is a large complex oligosaccharide composed of up to 50,000 pairs of disaccharide glucuronate-β (1-3) N-acetylglucosamine-amine β (1-4) as a basic unit. It is found in vivo as a major component of the extracellular matrix. Its tertiary structure is in the form of a random coil with a diameter of about 50 nm.
Hyaluronic acid (HA) has been used systemically or locally to treat diseases and diseases of the human body because of its ability to target active substances to sites of disease or disease (International Patent Publications No. WO 91 / 041058 & WO 93/16733). It is known that HA is formed in injured carotid arteries (for uninjured contralateral arteries) and colotectal tumors in experimental animals and is known to be retained in the skin of such experimental animals.
Since the vitreous space in the retina is composed of a negative material, particles coated with branched PEI do not pass through the vitreous structure due to mutual attractive force of (+) charge and (-) charge, . The nanoparticles of the present invention are coated with the outer layer of hyaluronic acid so that the particles are entirely negatively charged, thereby preventing the particles from clumping with the vitreous material to prevent them from being disturbed.
In addition, the retina consists of several cell layers, of which the inner limiting membrane has a pore structure of 10-20 nm and the external limiting membrane has a physical barrier of 3 to 3.4 nm.
The nanoparticles of the present invention have a particle size of 50 to 500 nm, preferably 100 to 400 nm, more preferably 150 to 300 nm.
Although the nanoparticles can not overcome the physical barrier of the retina in consideration of their size, they react with the CD44 receptor of muller cells by HA coated on the outer shell of the nanoparticles to pass through the retina by endocytosis or transcytosis can do. That is, the nanoparticles of the present invention can reach the outer retina efficiently by having the HA outer layer.
In another aspect, the invention relates to a method of making a nanoparticle for delivering a dielectric drug. FIG. 2 illustrates a method of preparing nanoparticles for dielectric transmission according to an embodiment of the present invention. Referring to FIG.
The method includes a condensation step and an outer layer coating step.
The condensing step is a step of mixing the nucleic acid targeting the gene and the cationic polymer and condensing them by ionic interaction.
For example, the condensation can be achieved by mixing the polymerized poly-siRNA (10 mg / ml) in a 1: 1 w / w ratio with 10 K branched PEI (bPEI, 1 mg / ml) 6.5 to 7.5).
The weight ratio of the nucleic acid (for example, poly-siRNA) to the cationic polymer may be 1: 0.1 to 3, preferably 1: 0.1 to 2. In an environment where the w / w ratio is more than 1: 1, the nanoparticles can be aggregated if they are further condensed and more than 1: 2 of the cationic polymer is added.
The nucleic acid may be small interfering RNA (siRNA) or antisense nucleic acids. The nucleic acid may be a gene targeting vascular endothelial growth factor (VEGF) in the retina.
The method may further include a step of preparing a nucleic acid in the form of a polymer by combining a plurality of the nucleic acids before the condensing step.
For example, about twelve siRNAs can be disulfide linked to form poly-siRNAs.
The contents of the nanoparticles described above can be referred to for the condensation step.
The coating step is a step of coating the outer layer of hyaluronic acid on the outer surface of the condensed core part. Preferably, the method may coat the outer layer with an electrostatic attraction between the (+) charge of the core and the (-) charge of the hyaluronic acid.
The hyaluronic acid may be 1: 0.5 to 2 (nucleic acid: hyaluronic acid), preferably 1: 1, in weight ratio with respect to the nucleic acid (for example, poly-siRNA). hyaluronic acid can be used at a ratio of 1: 1 (w / w) or more based on poly-siRNA, but the addition of hyaluronic acid further does not increase the coating layer in particular. The coating reaction is carried out at room temperature and at neutral pH (6.5 to 7.5).
For the coating step, the contents of the nanoparticles described above can be referred to.
Hereinafter, preferred embodiments of the present invention will be described in order to facilitate understanding of the present invention. However, the following embodiments are provided for the purpose of easier understanding of the present invention, but the present invention is not limited thereto.
Example 1
Synthesis of nanoparticles
SiRNAs targeting vascular endothelial growth factor A (VEGF-A) in rats were first synthesized. The VEGF sense is 5'-AUGUGAAUGCAGACCAAAGAA TT-3 'and the antisense is 5'-UUCUUUGGUCUGCAUUCA CAU TT-3'.
1 mg of the siRNA with the above sequence (bioneer, 0.0706 mu mol) was dissolved in distilled water, and DTT (dithiothreitol) was added thereto to add the -SH group at the 5 'end.
The solution was lyophilized to obtain siRNA, and then siRNA was added to 10 mM 500 [mu] l HEPES buffer. The reaction mixture was reacted with N, N, N, N-tetramethylazodicarboxamide (1 mg, 5.8 μmol) at room temperature for one day to synthesize poly-siRNA.
Next, 1 mg of the synthesized poly-siRNA was dissolved in 100 占 퐇 of distilled water and mixed with 1 mg / ml of 10K branched-PEI (Polyscience Asia Pacific). Condensed core particles (poly-siRNA / bPEI complex) were obtained after incubation at room temperature for 10 minutes.
1 mg (2 mol) of 5K HA (Lifecore biomedical) dissolved in 100 占 퐇 of distilled water was mixed with the obtained core particles at a weight ratio of 1 (w / w). The mixture was incubated for 5 minutes and then the nanoparticles (siRNA-polyplex) HA coated on the outside with a centrifuge (Amicon Ultra-0.5) were obtained.
Characterization of manufactured nanoparticles
The size distribution of the prepared nanoparticles (siRNA-polyplex) and HA-uncoated core particles (poly-siRNA / bPEI complex) is shown in FIG.
The size distribution of the core particles is 144.28 ± 15.19 nm, and the size distribution of the nanoparticles (siRNA-polyplex) is 260.7 ± 43.27 nm. The difference in size between them corresponds to 88.4 to 144.5 nm, and the difference corresponds to the thickness of the HA layer coated on the outer periphery.
TEM images of the nanoparticles are shown in FIG. The inside of the yellow dotted line indicates the core particle (poly-siRNA / bPEI complex), and the outer layer indicated by the arrow indicates the HA layer.
Cell adsorption test
Human ARPE-19 cells were seeded in 3 × 10 4 plates in 12 well plates and incubated for 24 hours. In each well, the TRITC-stained nanoparticles of Example 1 (siRNA-polyplex) were mixed with serum free medium at a concentration of 6 μg / μl. Then, after 3 hours and 12 hours, the cells were fixed with 4% PFA and stained with DAPI, and observed with a fluorescence microscope, and the results are shown in FIG. 5A.
mRNA expression inhibition test
2 × 10 5 B16F10 mouse melanoma cells were seeded on a 6-well plate, and then mono-siRNA, poly-siRNA, no treatment (CTL), lipofectamine (Lipo), and siRNA-polyplex ) Were mixed with serum free medium. After that, all cells were removed to extract mRNA, and cDNAs were prepared for mouse vegf-a and mouse beta actin. The cDNAs were amplified by PCR cyclers to confirm the level of mRNA. For quantitative analysis, real-time PCR 5B and 5C, respectively.
Referring to FIG. 5A, since no nanoparticle (siRNA-polyplex) was treated in CTL, it was confirmed that no glare of red wavelength was detected at all. When treated with nanoparticles (siRNA-polyplex), the siRNA-polyplex was injected into the cells over time and was found to be located around the nucleus stained with DAPI (blue). After 12 h, siRNA was released from the siRNA- It was confirmed that a ginkgo was spreading.
5B shows that only Lipo and polyplex groups, which are commercialized agents, have degraded without mouse VEGF-A mRNA. In other words, the nanoparticles (siRNA-polyplex) inhibit the expression of mouse VEGF-A in mouse melanoma B16F10 cells. mouse beta actin is the data confirming that PCR and mRNA - cDNA synthesis are well done.
FIG. 5C is data obtained by quantitative analysis while amplifying by real-time PCR. In the case of nanoparticles (siRNA-polyplex), mono and poly-siRNA inhibit VEGF-A expression up to 6.4% compared to the absence of mRNA degradation.
Eye dispersion experiment
6-8 weeks of C57BL / 6J mice were used. A siRNA-polyplex made of TRITC-stained poly-siRNA is injected into a mouse eye using a Hamilton syringe. After 3, 24 h, eyeballs were extracted and placed in OCT compound to make a block shape, and eye slice was made with cryostat. Then, the cell nuclei were stained with DAPI solution for 24 hours, and observed with a synchrotron microscope, which is shown in FIG.
Referring to FIG. 6, it can be seen that fluorescence is deeply observed in the retina into which nanoparticles (siRNA-polyplex) are injected compared with CTL in which nothing is injected. The amount of polyplex that permeates the retina over time increases the fluorescence intensity, confirming that the siRNA-polyplex reaches the RPE cell layer of the retina.
CNV inhibition test
6-8 weeks of C57BL / 6J mice were used. Anesthesia and shodong agents were administered to the eye and then irradiated to the RPE layer with a green Argon laser (532 nm) instrument: Lumenis Selecta Duet SLT (Lumenis, Santa Clara, CA, USA). The CNV was observed in the eye of the irradiated rats. After 7 days of laser irradiation, siRNA-polyplex was intraocularly injected with Hamilton syringe. After 14 days, dextran-fitc was injected into the heart of the rat to stain the blood vessels. Flat-mounted eyeballs were observed with a light microscope. FIG. 7 shows the CNV area analysis using an image J program.
In the flat-mounted CNV image of FIG. 7A, it can be seen that the CNV injected with the siRNA-polyplex was much smaller than the other groups (mono-siRNA, poly-siRNA). It was confirmed that all the major blood vessels causing CNV were reduced. From the upper left part of FIG. 7A, CTL, mono type siRNA injected with nothing, mono which is a polymer type but poly type siRNA which is not bonded with a polymer, poly siRNA finally made with poly-siRNA -polyplex.
For quantitative analysis of the CNV area, the CNV area was measured using the image J program. As a result, it was confirmed that the nanoparticle (siRNA-polyplex) was reduced to about half of the CTL.
Toxicity experiment
MTT assay: Thiazolyl Blue Tetrazolium Bromide (MTT) is dissolved in PBS at 5 mg / ml to make a solution. The MTT solution reacts in the mitochondria within the cell to form a chromogenic material that absorbs a specific wavelength band, which is indirectly known by the number of cells. The human ARPE-19 cell line is the abbreviation of the human retinal pigment epithelium cell and is the target cell to which this dielectric particle should deliver. 2 x 10 4 ARPE-19 cells are seeded in a 96-well plate and incubated for 24 hours. Cells were plated in serum-free medium, HA, bPEI, siRNA-polyplex, PBS (based on 100 nmol of poly-siRNA used in siRNA-polyplex) and then washed with DPBS after 24, 48, After 6 hours, 100 μl of DMSO was treated and cell viability was measured with a plate reader.
Hematoxylin and eosin stain: Hematoxylin and eosin stain (H & E stain)
A commonly used tissue analysis method is to put the tissue into paraffin, make a block, make slices of appropriate size, remove paraffin by xylene 3-5 times washing, and stain with hematoxylin (nuclei staining). Then remove the remaining hematoxylin with 1% HCL. It is then stained with Eosin (cytoplasmic stain). It was observed that each cell layer of the slice of the eyeball was changed when the particles were injected.
8A, it can be seen that the polymer used in making the siRNA-polyplex and the produced siRNA-polyplex have little or no toxicity to human ARPE cells. 24, 48 and 72 h, respectively, the MTT assay results showed no significant difference when compared with the untreated CTL.
The siRNA-polyplex injected into the mouse eye was also less toxic than the PBS (positive) and no cells due to immune reactions such as macrophage changes or cell layer changes in the eye tissues compared to the negative Able to know.
It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the present invention as defined by the appended claims.
10:
11: Nucleic acid 12: Cationic polymer
Claims (15)
And a hyaluronic acid outer layer coated on an outer surface of the core part.
And coating an outer layer of hyaluronic acid with an electrostatic attraction on the outer surface of the condensed core portion.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020140056221A KR20150129873A (en) | 2014-05-12 | 2014-05-12 | Nanoparticles for genes drug delivery and method for preparing the same |
PCT/KR2015/004684 WO2015174703A1 (en) | 2014-05-12 | 2015-05-11 | Nanoparticles for gene drug delivery, and preparation method therefor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020140056221A KR20150129873A (en) | 2014-05-12 | 2014-05-12 | Nanoparticles for genes drug delivery and method for preparing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20150129873A true KR20150129873A (en) | 2015-11-23 |
Family
ID=54480194
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020140056221A KR20150129873A (en) | 2014-05-12 | 2014-05-12 | Nanoparticles for genes drug delivery and method for preparing the same |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR20150129873A (en) |
WO (1) | WO2015174703A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018143493A1 (en) * | 2017-02-03 | 2018-08-09 | 서강대학교 산학협력단 | Sirna hydrogel-based nanoparticles for treating atopic diseases, and preparation method therefor |
WO2023249386A1 (en) * | 2022-06-20 | 2023-12-28 | 서강대학교 산학협력단 | Melittin-based nanoparticle composite and method for preparing same |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100806088B1 (en) * | 2007-08-09 | 2008-02-21 | 고려대학교 산학협력단 | Compositions for delivering nucleic acids using cationic polymer conjugates consisting of hyaluronic acid and polyethylenimine |
KR101678876B1 (en) * | 2010-01-15 | 2016-11-23 | 한국과학기술원 | Multi-conjugate of siRNA targeting multiple genes and preparing method thereof |
-
2014
- 2014-05-12 KR KR1020140056221A patent/KR20150129873A/en active Search and Examination
-
2015
- 2015-05-11 WO PCT/KR2015/004684 patent/WO2015174703A1/en active Application Filing
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018143493A1 (en) * | 2017-02-03 | 2018-08-09 | 서강대학교 산학협력단 | Sirna hydrogel-based nanoparticles for treating atopic diseases, and preparation method therefor |
WO2023249386A1 (en) * | 2022-06-20 | 2023-12-28 | 서강대학교 산학협력단 | Melittin-based nanoparticle composite and method for preparing same |
Also Published As
Publication number | Publication date |
---|---|
WO2015174703A1 (en) | 2015-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yang et al. | Self-assembled double-bundle DNA tetrahedron for efficient antisense delivery | |
US9567430B2 (en) | Enzymatic synthesis of poly(amine-co-esters) and methods of use thereof for gene delivery | |
O’Rorke et al. | Non-viral polyplexes: Scaffold mediated delivery for gene therapy | |
US7815941B2 (en) | Nucleic acid microspheres, production and delivery thereof | |
Li et al. | Ionizable lipid-assisted efficient hepatic delivery of gene editing elements for oncotherapy | |
US8492142B2 (en) | Freeze-dried product for introducing nucleic acid, oligonucleic acid or derivative thereof | |
Tang et al. | Soft materials as biological and artificial membranes | |
Pyykkö et al. | An overview of nanoparticle based delivery for treatment of inner ear disorders | |
Heitz et al. | Stereoselective pH responsive peptide dendrimers for siRNA transfection | |
US20230052784A1 (en) | A delivery system comprising silicon nanoparticles | |
Dube et al. | Evaluation of doxorubicin-loaded 3-helix micelles as nanocarriers | |
Huang et al. | Enhanced delivery of siRNA to retinal ganglion cells by intravitreal lipid nanoparticles of positive charge | |
KR101880790B1 (en) | Nanoparticles for genes drug delivery with siRNA for the long -term treatment of retinal disorders and method for preparing the same | |
Lee et al. | Anti-VEGF polysiRNA polyplex for the treatment of choroidal neovascularization | |
Geinguenaud et al. | Vectorization of nucleic acids for therapeutic approach: tutorial review | |
Supe et al. | Liposome-polyethylenimine complexes for the effective delivery of HuR siRNA in the treatment of diabetic retinopathy | |
Xiao et al. | Preparation of [amine-terminated generation 5 poly (amidoamine)]-graft-poly (lactic-co-glycolic acid) electrospun nanofibrous mats for scaffold-mediated gene transfection | |
US20110159098A1 (en) | Stabilization and delivery of nucleic acid complexes | |
Sun et al. | Bioactive Phosphorus Dendrimers as a Universal Protein Delivery System for Enhanced Anti-inflammation Therapy | |
Xie et al. | Hepatic carcinoma selective nucleic acid nanovector assembled by endogenous molecules based on modular strategy | |
KR20150129873A (en) | Nanoparticles for genes drug delivery and method for preparing the same | |
Fletcher et al. | Nonviral in vivo delivery of CRISPR-Cas9 using protein-agnostic, high-loading porous silicon and polymer nanoparticles | |
WO2018140411A2 (en) | Therapeutic polymeric nanoparticles for tailored gene expression | |
KR100533247B1 (en) | Gene Delivery system by Urocanic Acid-Modified Chitosan | |
Wang et al. | Compounding engineered mesenchymal stem cell-derived exosomes: A potential rescue strategy for retinal degeneration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
N231 | Notification of change of applicant | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E90F | Notification of reason for final refusal | ||
E601 | Decision to refuse application | ||
AMND | Amendment |